We would like to inform you that due to the containment measures for the Coronavirus outbreak the normal activity of AIBILI could be affected. However a contingence plan is already in place allowing our collaborators to work from home.
AIBILI apologises in advance for any inconvenience this may cause. We appreciate your understanding and hope we will all overcome this exceptional situation rapidly.
O Livro Branco das Doenças Raras é o resultado de um esforço conjunto do Grupo de Trabalho das Doenças Raras da P-BIO e do Centro de Avaliação de Tecnologias de Saúde e Investigação do Medicamento da AIBILI contando com a participação de quinze especialistas. O documento foi coordenado pelo Prof. Doutor Francisco Batel Marques, bem como pelo Dr. Joaquim Marques, coordenador do Grupo de Trabalho das Doenças Raras da P-BIO. O documento teve como objetivo inicial ser “uma compilação isenta, objetiva e técnico-cientificamente bem fundamentada sobre o panorama do diagnóstico, tratamento e investigação das doenças raras em Portugal”, começa por dizer o Prof. Doutor Francisco Batel Marques. Veja aqui o vídeo com a entrevista realizada pela NewsFarma ao Prof. Doutor Francisco Batel Marques.
A AIBILI e a ESEnfC assinaram um acordo de parceria para o desenvolvimento de atividades de investigação clínica destas duas instituições da cidade de Coimbra. Encontram, aqui, o comunicado de imprensa.
Nesta edição do boletim “FARMACOVIGILÂNCIA: Atualizações de segurança de medicamentos” informa-se acerca de várias questões relacionadas com a segurança de domperidona, nivolumab, carfilzomib, mebutato de ingenol, prescrição de fármacos na insuficiência renal, alemtuzumab, tofacitinib e haloperidol. São ainda apresentadas as atividades científicas e os resultados das atividades da Unidade de Farmacovigilância de Coimbra (UFC), referentes ao quarto trimestre de 2019.
Farmacovigilância: Atualizações de segurança de medicamentos – Vol. 6, Nº 4 – 4º Trimestre .
Consulte: Farmacovigilancia – Atualizações de segurança de medicamento Vol. 6 – N 4
A CUF e a AIBILI estabeleceram uma parceria para o desenvolvimento de investigação clínica que irá permitir reforçar as competências de ambas as instituições e unir esforços para a concretização de projetos relevantes, nomeadamente na área da Oftalmologia. Encontram, aqui, o comunicado de imprensa.
AIBILI aims to reinforce its Health Technology Assessment and Drug Research Centre with a Researcher on Economic Evaluation of Health Technologies
Applications here: https://www.aibili.pt/candidaturas/
Read here the interview to Dr Cecilia Martinho on OFTALPRO, where she talks about the importance of EVICR.net and how it promotes Portugal as a reference in Clinical Research in Ophthalmology.
The journal Ophthalmic Research has just published a commemorative issue in Honour of Professor José Cunha-Vaz and his achievements in Diabetic Retinopathy, and ground-breaking contribution to basic science and clinical research on vascular retinal disease.
It is a special issue that includes a collection of essays authored by eminent scientists on diabetic retinopathy (DR) and diabetic macular edema (DME). Topics include the gold standard of grading DR by the Early Treatment of Diabetic Retinopathy Study (ETDRS) group, the pathophysiology of DR, the characterization of the initial stages of DME, DR within the spectrum of diabetic complications, screening approaches for DR, contributions of the Diabetic Retinopathy Clinical Research Network (DRCR.net) to the treatment of DR, and the role of steroids for treating DME.
Prof. Cunha-Vaz is Emeritus Professor of Ophthalmology of the Coimbra University, Portugal, and President of AIBILI. He was the ninth Editor-in-Chief of Ophthalmic Research and is now Honorary Editor. He is also the Diabetic Retinopathy and Vascular Diseases Expert Committee Coordinator of the EVICR.net.
His work includes laboratory and clinical research in retina and intraocular fluids with a special emphasis on blood-retinal barriers and DR. He was the first to identify the anatomical basis of the blood-retinal barrier, tight junctions in retinal vessels and an active transport system in retinal vessels and retinal pigment epithelium. Later, he introduced the concept of multimodal macula mapping and identified different phenotypes of non-proliferative DR in type 2 diabetes. Prof. Cunha-Vaz and his group identified microaneurysm turnover as a biomarker for DR progression towards clinically significant DME. Recently, he has played a pivotal role in the development of OCT leakage as a new method to identify and locate abnormal fluid accumulation in diabetic retinal edema.
With more than 500 peer-reviewed papers and books in is curriculum, the merit of Prof. Cunha-Vaz is recognized worldwide and unquestionable. For AIBILI it is also an honour to see his work being acknowledge by his peers.
To access this issue click here
The 1st Meeting of the Drug Safety and Effectiveness Network (DruSER.net) took place on December 13, 2019.
It was an important event to present this network coordinated by CHAD-AIBILI and the relevant work that is being made in the field of drug safety, effectiveness, real-world data and pharmacovigilance.
The evented counted with more than 75 participants, including students, representative of primary health care units and pharmacovigilance units, also from entities with high impact in the field, as the National Pharmacies Association and INFARMED.
AIBILI wishes you a joyous Holiday Season and a prosperous New Year!
